US Stock MarketDetailed Quotes

PTCT PTC Therapeutics

Watchlist

25.970
+0.650+2.57%

Close Apr 22 16:00 ET

1.99BMarket Cap-3102P/E (TTM)

PTC Therapeutics Stock Forum

Moomoo AI

Mar 3 22:56

PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.

There's No Escaping PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Muted Revenues Despite A 27% Share Price Rise

Moomoo AI

Feb 14 22:26

Recent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.

PTC Therapeutics Insiders Sold US$1.1m Of Shares Suggesting Hesitancy

Moomoo AI

Nov 18, 2023 22:43

PTC Therapeutics' ongoing losses may have led to negative market view, causing a contradictory movement in the stock against the company’s revenue growth. The firm's underperformance in the past five years suggests unresolved issues. Currently, the healthcare company has five investment analysis warning signs.

PTC Therapeutics (NASDAQ:PTCT) Adds US$145m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 68%

amiable Hedgehog_758

Oct 20, 2023 02:39

$PTC Therapeutics(PTCT.US)$ 🚀🚀🚀🚀🚀🚀🚀🔥🔥🔥🔥🔥🔥🔥 Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- R...

BrandonnW

Sep 23, 2021 15:22

PTC Therapeutics, Inc. today announced positive results from a long-term real-world study of Translarna (Ataluren), a small molecule therapy. Data from 241 patients showed that Translarna delayed bedside mobility by more than 5 years and reduced lung function by an average of 1.8 years in boys with nonsense mutant Duchenne muscular dystrophy compared with standard therapy alone.$PTC Therapeutics(PTCT.US)$

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall